Gilead stuffs another NASH drug discovery program into a growing portfolio
When Daniel O’Day shows up for work as the new CEO of Gilead $GILD later this year, he’ll inherit a bustling R&D operation centered on its experimental drugs for NASH.
Their late-stage reveal on selonsertib — along with a similar unveiling from Intercept — is one of the most anticipated events of the year. And Gilead has two other mid-stage drugs in the pipeline to help build what it hopes will be an industry-leading cocktail for NASH, much like they did for HIV and hepatitis C. Those 3 clinical drugs make up half of the 6 drugs Gilead lists in its pipeline for liver diseases, including hepatitis B.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.